Telix Pharmaceuticals Ltd
Company Profile
Business description
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Contact
55 Flemington Road
Level 4, North Melbourne
MelbourneVIC3051
AUST: +61 390933855
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,184
Telix Pharmaceuticals Ltd News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
stocks
Revenue growth on track for undervalued ASX healthcare stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,975.82 | 5.82 | 0.07% |
| DAX 40 | 25,885.91 | 153.77 | -0.59% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,744.28 | 22.21 | 0.21% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |